Aligos Therapeutics (ALGS)
(Delayed Data from NSDQ)
$0.49 USD
-0.05 (-8.49%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $0.48 -0.01 (-1.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALGS 0.49 -0.05(-8.49%)
Will ALGS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALGS
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
Other News for ALGS
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
Aligos Therapeutics announces collaboration with Xiamen Amoytop Biotech
Aligos Therapeutics (ALGS) Receives a Buy from Piper Sandler